In the COMBI-i trial, the objective response rate of combined spartalizumab (anti-PD-1 inhibitor), dabrafenib, and trametinib was 78% in advanced BRAF-mutant melanoma, and 44% of patients achieved a complete response. This evidence concerns the gene BRAF and melanoma.